ResearcherJapan Society for the Promotion of ScienceNo recent work listed
Tomohiro Kondo
Matched on ORCID iD 0000-0001-5102-2654; OpenAlex author ID A5051329577. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers
Papers 6
- Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
- Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicente… Co-author DOI 10.1007/s12032-023-02011-y↗
- BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001672↗
- Natural History of Pancreatic Ductal Adenocarcinoma Diagnosed During Observation of Other Organ Cancers. First author DOI 10.12659/ajcr.917197↗
- Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Co-author DOI 10.18632/oncotarget.24865↗
- Conversion therapy for pancreatic cancer with peritoneal metastases using intravenous and intraperitoneal paclitaxel with S-1. Co-author DOI 10.3892/mco.2016.1051↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Manabu Muto · 3 shared papers, 2018–2023 · strength 0.31
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreati… DOI 10.1097/mpa.0000000000001672↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Masashi Kanai · 3 shared papers, 2018–2023 · strength 0.31
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreati… DOI 10.1097/mpa.0000000000001672↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Junichi Matsubara · 2 shared papers, 2020–2023 · strength 0.24
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreati… DOI 10.1097/mpa.0000000000001672↗
- Tadayuki Kou · 2 shared papers, 2018–2023 · strength 0.21
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Toshihiko Masui · 2 shared papers, 2018–2023 · strength 0.21
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Toshinao Itani · 1 shared paper, 2023 · strength 0.14
- Michio Yoshimura · 1 shared paper, 2023 · strength 0.14
- Kazuto Nishio · 1 shared paper, 2020 · strength 0.10
- Yutaka Okagawa · 1 shared paper, 2019 · strength 0.09
- Hitoshi Gene Kondo · 1 shared paper, 2019 · strength 0.09
- Yuzo Kodama · 1 shared paper, 2018 · strength 0.07
- Kyoichi Takaori · 1 shared paper, 2018 · strength 0.07
- Yumiko Oyamada · 1 shared paper, 2016 · strength 0.06
- Hiromitsu Kitayama · 1 shared paper, 2016 · strength 0.06
- Satoshi Hirano · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.